Evaluation of treatment response in patients with recurrent grade 4 glioma using hyperpolarized [1- 13C]pyruvate MRI

Hyperpolarized (HP) [1- ¹³ C]pyruvate MRI can noninvasively detect dynamic metabolic activity in the brain. This study utilizes HP-[1- ¹³ C]pyruvate MRI to monitor treatment-related metabolism and evaluate early therapeutic response in twenty patients with recurrent grade 4 glioma undergoing cytotoxic, antiangiogenic, and targeted chemotherapies. Metabolic changes within the T2-lesion and normal-appearing white matter were compared among patients with similar treatments and/or outcomes. The lactate/pyruvate ratio increased by 14.3% at 1 month in the group whose therapy included bevacizumab, while it decreased by 13.1% at 2 months in the normal-appearing white matter of patients on everolimus. In the T2-lesion, patients on bevacizumab showed a 24.3% increase, whereas patients on everolimus showed a 7.6% decrease in normalized lactate/pyruvate ratios. Patients with shorter 6-month progression-free survival showed an average 9.6% increase in the lactate/pyruvate ratio as early as 1 month after treatment. This study demonstrates the potential of real-time metabolic imaging for response monitoring in patients with glioma.